| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BRIEF COMMUNICATIONS |
,
* Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School,
Department of Biological Chemistry and Molecular Pharmacology, and
Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts
Correspondence: Dr. Raghu Kalluri, Department of Medicine, Harvard Medical School, Division of Matrix Biology, Department of Medicine, CLS 11086, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, 3 Blackfan Circle, Boston, MA 02215. Phone: 617-735-4601; Fax: 617-735-4602; E-mail: rkalluri{at}bidmc.harvard.edu
Received for publication May 19, 2008. Accepted for publication August 18, 2008.
Fibroblasts are key mediators of fibrosis in the kidney and other organs, but their origin during fibrosis is still not completely clear. Activated fibroblasts likely arise from resident quiescent fibroblasts via epithelial-to-mesenchymal transition and from the bone marrow. Here, we demonstrate that endothelial cells also contribute to the emergence of fibroblasts during kidney fibrosis via the process of endothelial-to-mesenchymal transition (EndMT). We examined the contribution of EndMT to renal fibrosis in three mouse models of chronic kidney disease: (1) Unilateral ureteral obstructive nephropathy, (2) streptozotocin-induced diabetic nephropathy, and (3) a model of Alport renal disease. Approximately 30 to 50% of fibroblasts coexpressed the endothelial marker CD31 and markers of fibroblasts and myofibroblasts such as fibroblast specific protein-1 and
-smooth muscle actin. Endothelial lineage tracing using Tie2-Cre;R26R-stop-EYFP transgenic mice further confirmed the presence of EndMT-derived fibroblasts. Collectively, our results demonstrate that EndMT contributes to the accumulation of activated fibroblasts and myofibroblasts in kidney fibrosis and suggest that targeting EndMT might have therapeutic potential.
Related Articles
J. Am. Soc. Nephrol. 2008 19: A10.
J. Am. Soc. Nephrol. 2008 19: 2246-2248.
This article has been cited by other articles:
![]() |
K. Sanchez-Pozos, F. Lee-Montiel, R. Perez-Villalva, N. Uribe, G. Gamba, B. Bazan-Perkins, and N. A. Bobadilla Polymerized type I collagen reduces chronic cyclosporine nephrotoxicity Nephrol. Dial. Transplant., February 5, 2010; (2010) gfq020v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Mene and N. Pirozzi Potassium channels: the 'master switch' of renal fibrosis? Nephrol. Dial. Transplant., February 1, 2010; 25(2): 353 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu New Insights into Epithelial-Mesenchymal Transition in Kidney Fibrosis J. Am. Soc. Nephrol., February 1, 2010; 21(2): 212 - 222. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-D. Liao, X.-P. Yang, M. D'Ambrosio, Y. Zhang, N.-E. Rhaleb, and O. A. Carretero N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Attenuates Renal Injury and Dysfunction in Hypertensive Rats With Reduced Renal Mass: Council for High Blood Pressure Research Hypertension, February 1, 2010; 55(2): 459 - 467. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Humphreys, S.-L. Lin, A. Kobayashi, T. E. Hudson, B. T. Nowlin, J. V. Bonventre, M. T. Valerius, A. P. McMahon, and J. S. Duffield Fate Tracing Reveals the Pericyte and Not Epithelial Origin of Myofibroblasts in Kidney Fibrosis Am. J. Pathol., January 1, 2010; 176(1): 85 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, X. Qu, and J. F. Bertram Endothelial-Myofibroblast Transition Contributes to the Early Development of Diabetic Renal Interstitial Fibrosis in Streptozotocin-Induced Diabetic Mice Am. J. Pathol., October 1, 2009; 175(4): 1380 - 1388. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kizu, D. Medici, and R. Kalluri Endothelial-Mesenchymal Transition as a Novel Mechanism for Generating Myofibroblasts during Diabetic Nephropathy Am. J. Pathol., October 1, 2009; 175(4): 1371 - 1373. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Grgic, E. Kiss, B. P. Kaistha, C. Busch, M. Kloss, J. Sautter, A. Muller, A. Kaistha, C. Schmidt, G. Raman, et al. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels PNAS, August 25, 2009; 106(34): 14518 - 14523. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Hewitson Renal tubulointerstitial fibrosis: common but never simple Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1239 - F1244. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. Fedorova, V. Raju, N. El-Okdi, A. Shidyak, D. J. Kennedy, S. Vetteth, D. R. Giovannucci, A. Y. Bagrov, O. V. Fedorova, J. I. Shapiro, et al. The cardiotonic steroid hormone marinobufagenin induces renal fibrosis: implication of epithelial-to-mesenchymal transition Am J Physiol Renal Physiol, April 1, 2009; 296(4): F922 - F934. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Strutz How Many Different Roads May a Cell Walk down in Order to Become a Fibroblast? J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2246 - 2248. [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673